Invention Grant
US08664252B2 Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
有权
用于治疗肥大性心肌病的磷酸二酯酶III型（PDE III）抑制剂或CA2 +敏化剂
- Patent Title: Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
- Patent Title (中): 用于治疗肥大性心肌病的磷酸二酯酶III型（PDE III）抑制剂或CA2 +敏化剂
-
Application No.: US13126541Application Date: 2009-11-23
-
Publication No.: US08664252B2Publication Date: 2014-03-04
- Inventor: Juergen Daemmgen , Olaf Joens
- Applicant: Juergen Daemmgen , Olaf Joens
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim Vetmedica GmbH
- Current Assignee: Boehringer Ingelheim Vetmedica GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Michael P. Morris; Wendy M. Gombert
- Priority: EP08169897 20081125
- International Application: PCT/EP2009/065618 WO 20091123
- International Announcement: WO2010/060874 WO 20100603
- Main IPC: A01N43/52
- IPC: A01N43/52 ; A61K31/415 ; A01N43/58 ; A61K31/50
Abstract:
The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.
Public/Granted literature
Information query
IPC分类:
